샘플 요청 목록

 카트 문의
시장보고서
상품코드
1761077

세계의 척추 생물학적 제제 시장

Spine Biologics
발행일: | 리서치사: Global Industry Analysts, Inc. | 페이지 정보: 영문 196 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

척추 생물학적 제제 세계 시장은 2030년까지 29억 달러에 달할 전망

2024년에 22억 달러로 추정되는 척추 생물학적 제제 세계 시장은 분석 기간인 2024-2030년에 CAGR 4.4%로 성장하여 2030년에는 29억 달러에 달할 것으로 예측됩니다. 이 보고서에서 분석한 부문 중 하나인 척추 이식편은 CAGR 3.9%를 기록하며 분석 기간 종료시에는 14억 달러에 달할 것으로 예측됩니다. 골이식 대체물 부문의 성장률은 분석 기간 동안 CAGR 5.0%로 추정됩니다.

미국 시장은 5억 9,320만 달러로 추정, 중국은 CAGR 6.8%로 성장 예측

미국의 척추 생물학적 제제 시장은 2024년에 5억 9,320만 달러로 추정됩니다. 세계 2위 경제 대국인 중국은 분석 기간인 2024-2030년 CAGR 6.8%로 2030년까지 5억 9,380만 달러의 시장 규모에 달할 것으로 예측됩니다. 기타 주목할 만한 지역별 시장으로는 일본과 캐나다가 있고, 분석 기간 동안 CAGR은 각각 2.5%와 3.6%로 예측됩니다. 유럽에서는 독일이 CAGR 3.0%로 성장할 것으로 예측됩니다.

세계의 척추 생물학적 제제 시장 - 주요 동향과 촉진요인 정리

척추 생물학적 제제가 척추 수술과 회복에 변화를 가져오는 이유는 무엇인가?

척추 생물학적 제제는 뼈 재생, 유합 강화, 조직 회복을 위한 혁신적인 솔루션을 제공함으로써 척추 수술 및 회복에 변화를 가져옵니다. 골이식편, 성장인자, 줄기세포, 합성 생체재료를 포함한 이들 생물학적 제제는 척추 고정술, 추간판 치환술, 척추 변형 교정술에 널리 사용되고 있습니다. 퇴행성 디스크, 척추측만증, 외상 관련 손상 등 척추 질환의 유병률이 증가함에 따라 유착률을 개선하고, 치유 시간을 단축하며, 합병증을 최소화하는 생물학적 제제에 대한 수요가 빠르게 증가하고 있습니다. 척추 생물학적 제제는 특히 최소침습 척추수술(MISS) 및 복잡한 척추 재건술에서 환자에게 더 나은 임상적 결과와 빠른 회복을 가져다 줄 수 있습니다.

기술 발전은 척추 생물학적 제제 시장에 어떤 영향을 미치고 있는가?

생체재료, 합성골이식편, 세포 기반 치료법의 기술 발전은 척추 생물학적 제제의 유효성, 안전성, 적용 범위를 크게 향상시키고 있습니다. 탈회골 매트릭스(DBM), 유전자재조합 인간성장인자, 동종 이식골 제품 등 차세대 생물학적 제제의 개발은 척추 고정 및 뼈 치유에 보다 효과적인 옵션을 제공하고 있습니다. 줄기세포를 이용한 치료법, 유전자 치료, 재생의료의 혁신은 조직 복구, 신경 재생, 맞춤형 척추 치료에 새로운 가능성을 제공하며 견인력을 높이고 있습니다. 또한, 여러 생물학적 제제와 합성 물질을 통합한 생물학적 제제의 조합과 하이브리드 솔루션의 출현은 척추 외과 의사가 이용할 수 있는 치료 옵션을 넓혀주며 척추 생물학적 제제 시장의 성장을 뒷받침하고 있습니다.

척추 생물학적 제제 산업의 성장을 주도하는 시장 세분화는?

제품 유형에는 골이식재, 골이식재 대체물, 혈소판풍부혈장(PRP), 골형성 단백질(BMP), 세포 기반 매트릭스 등이 있으며, 골이식재 대체물은 척추 고정술에 널리 사용되어 가장 큰 시장 점유율을 차지하고 있습니다. 척추 생물학적 제제의 용도는 척추 고정술, 추간판 치환술, 외상 복구술, 변형 교정술 등 다양하지만, 척추 고정술은 고정률을 높이고 뼈의 치유를 촉진하는 생물학적 제제에 대한 수요가 높기 때문에 지배적인 분야로 자리 잡고 있습니다. 최종 사용 분야에는 병원, 전문 클리닉, 연구기관이 포함되며, 병원은 고도의 수술 능력과 다학제적 치료팀으로 인해 시장을 주도하고 있습니다. 지리적으로 북미와 유럽은 재생의료와 첨단 생물학적 제제의 높은 채택률에 힘입어 척추 생물학적 제제의 가장 큰 시장이며, 아시아태평양은 의료 투자 증가와 척추 질환의 유병률 증가로 인해 빠르게 성장할 것으로 예상됩니다.

척추 생물학적 제제 시장의 성장 촉진요인은?

척추 생물학적 제제 시장의 성장은 최소침습 척추 수술(MISS)에서 생물학적 제제에 대한 수요 증가, 생체재료, 합성골이식편, 재생의료의 기술 발전, 유합률, 뼈 재생, 치유 시간 향상에 대한 관심 증가 등 여러 요인에 의해 이루어지고 있습니다. 다양한 척추 질환에 대해 효과적이고 안전하며 맞춤화된 생물학적 제제를 제공해야 할 필요성이 다양한 외과적 및 비외과적 환경에서 척추 생물학적 제제에 대한 수요를 주도하고 있습니다. 차세대 생물학적 제제, 줄기세포 치료, 유전자 치료, 생물학적 제제 병용의 기술 혁신은 재생의료, 합성 생체재료, 맞춤형 척추 치료의 발전과 함께 척추 생물학적 제제의 유효성, 안전성, 시장성을 높여 시장 성장을 뒷받침하고 있습니다. 외상, 추간판 변성증, 척추측만증 치료, 척추 변형 교정에서 생물학적 제제의 적용 확대, 근거 기반 진료, 임상 가이드라인, 환자 교육에 대한 중요성 증가는 시장 관계자들에게 새로운 기회를 창출하고 있습니다. 또한, 다양한 환자군을 위한 비용 효율적이고 확장 가능한 하이브리드 척추 생물학적 제제 개발에 집중하고 있는 것이 척추 생물학적 제제 시장의 성장을 더욱 촉진하고 있습니다.

부문

제품(척추 이식편, 골이식 대체물, 세포 기반 매트릭스), 최종사용자(병원, 외래 수술 센터(ASCs),기타 최종사용자)

조사 대상 기업 사례(총 46개사)

  • AlloSource
  • Alphatec Spine, Inc.
  • DePuy Synthes
  • Exactech, Inc.
  • Globus Medical, Inc.
  • Harvest Technologies
  • Medtronic, Inc.
  • NuVasive, Inc.

AI 통합

Global Industry Analysts는 검증된 전문가 컨텐츠와 AI 툴을 통해 시장 정보와 경쟁 정보를 혁신하고 있습니다.

Global Industry Analysts는 LLM 및 업계 고유의 SLM을 조회하는 일반적인 규범에 따르는 대신 비디오 기록, 블로그, 검색 엔진 조사, 방대한 양의 기업, 제품/서비스, 시장 데이터 등 세계 전문가로부터 수집한 컨텐츠 리포지토리를 구축했습니다.

관세 영향 계수

Global Industry Analysts는 본사의 국가, 제조거점, 수출입(완제품 및 OEM)을 기반으로 기업의 경쟁력 변화를 예측하고 있습니다. 이러한 복잡하고 다면적인 시장 역학은 매출원가(COGS) 증가, 수익성 감소, 공급망 재편 등 미시적 및 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예상됩니다.

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트
  • 기타 중동
  • 아프리카

제4장 경쟁

ksm

Global Spine Biologics Market to Reach US$2.9 Billion by 2030

The global market for Spine Biologics estimated at US$2.2 Billion in the year 2024, is expected to reach US$2.9 Billion by 2030, growing at a CAGR of 4.4% over the analysis period 2024-2030. Spinal Allografts, one of the segments analyzed in the report, is expected to record a 3.9% CAGR and reach US$1.4 Billion by the end of the analysis period. Growth in the Bone Graft Substitutes segment is estimated at 5.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$593.2 Million While China is Forecast to Grow at 6.8% CAGR

The Spine Biologics market in the U.S. is estimated at US$593.2 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$593.8 Million by the year 2030 trailing a CAGR of 6.8% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.5% and 3.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.0% CAGR.

Global Spine Biologics Market - Key Trends and Drivers Summarized

Why Are Spine Biologics Transforming Spine Surgery and Recovery?

Spine biologics are transforming spine surgery and recovery by offering innovative solutions for bone regeneration, fusion enhancement, and tissue repair. These biologics, which include bone grafts, growth factors, stem cells, and synthetic biomaterials, are widely used in spinal fusion procedures, disc replacement, and spinal deformity correction. With the increasing prevalence of spinal disorders such as degenerative disc disease, scoliosis, and trauma-related injuries, the demand for biologics that improve fusion rates, reduce healing times, and minimize complications is growing rapidly. Spine biologics are particularly advantageous in minimally invasive spine surgery (MISS) and complex spinal reconstructions, providing better clinical outcomes and faster recovery for patients.

How Are Technological Advancements Impacting the Spine Biologics Market?

Technological advancements in biomaterials, synthetic bone grafts, and cell-based therapies are significantly enhancing the effectiveness, safety, and application scope of spine biologics. The development of next-generation biologics, such as demineralized bone matrices (DBMs), recombinant human growth factors, and allograft bone products, is providing more effective options for spinal fusion and bone healing. Innovations in stem cell-based therapies, gene therapy, and regenerative medicine are gaining traction, offering new possibilities for tissue repair, nerve regeneration, and personalized spine care. Additionally, the emergence of combination biologics and hybrid solutions, which integrate multiple biologic agents and synthetic materials, is expanding the treatment options available for spine surgeons, supporting the growth of the spine biologics market.

Which Market Segments Are Leading the Growth of the Spine Biologics Industry?

Product types include bone grafts, bone graft substitutes, platelet-rich plasma (PRP), bone morphogenetic proteins (BMPs), and cell-based matrices, with bone graft substitutes holding the largest market share due to their widespread use in spinal fusion procedures. Applications of spine biologics span spinal fusion, disc replacement, trauma repair, and deformity correction, with spinal fusion being the dominant segment due to the high demand for biologics that enhance fusion rates and promote bone healing. End-use sectors include hospitals, specialized clinics, and research institutes, with hospitals leading the market due to their advanced surgical capabilities and multidisciplinary care teams. Geographically, North America and Europe are the largest markets for spine biologics, driven by high adoption of regenerative medicine and advanced biologic products, while Asia-Pacific is expected to witness rapid growth due to rising healthcare investments and increasing prevalence of spinal disorders.

What Are the Key Drivers of Growth in the Spine Biologics Market?

The growth in the spine biologics market is driven by several factors, including rising demand for biologics in minimally invasive spine surgery (MISS), technological advancements in biomaterials, synthetic bone grafts, and regenerative medicine, and the increasing focus on enhancing fusion rates, bone regeneration, and healing times. The need to provide effective, safe, and personalized biologics for a wide range of spinal conditions is driving the demand for spine biologics across various surgical and non-surgical settings. Technological innovations in next-generation biologics, stem cell-based therapies, gene therapy, and combination biologics, coupled with advancements in regenerative medicine, synthetic biomaterials, and personalized spine care, are enhancing the efficacy, safety, and marketability of spine biologics, supporting market growth. The expansion of biologic applications in trauma, degenerative disc disease, scoliosis treatment, and spinal deformity correction, along with the growing emphasis on evidence-based practice, clinical guidelines, and patient education, is creating new opportunities for market players. Additionally, the focus on developing cost-effective, scalable, and hybrid spine biologics for diverse patient populations is further propelling the growth of the spine biologics market.

SCOPE OF STUDY:

The report analyzes the Spine Biologics market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product (Spinal Allografts, Bone Graft Substitutes, Cell-Based Matrix); End-Use (Hospitals, Ambulatory Surgery Centers (ASCs), Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 46 Featured) -

  • AlloSource
  • Alphatec Spine, Inc.
  • DePuy Synthes
  • Exactech, Inc.
  • Globus Medical, Inc.
  • Harvest Technologies
  • Medtronic, Inc.
  • NuVasive, Inc.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Global Economic Update
    • Spine Biologics - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Demand for Biologics in Minimally Invasive Spine Surgery (MISS) Drives Spine Biologics Market Growth
    • Increasing Focus on Enhancing Fusion Rates, Bone Regeneration, and Healing Times Spurs Adoption of Spine Biologics
    • Technological Advancements in Biomaterials, Synthetic Bone Grafts, and Cell-Based Therapies Propel Market Innovation
    • Growing Emphasis on Reducing Post-Operative Complications and Repeat Surgeries Expands Addressable Market Opportunity
    • Emergence of Next-Generation Biologics, Growth Factors, and Stem Cell-Based Products Strengthens Business Case
    • Rising Adoption of Biologics in Lumbar, Cervical, and Thoracic Spine Procedures Accelerates Market Demand
    • Focus on Developing Combination Biologics and Hybrid Solutions for Enhanced Therapeutic Efficacy Drives Market Competitiveness
    • Growing Application of Spine Biologics in Trauma, Degenerative Disc Disease, and Scoliosis Treatment Fuels Market Expansion
    • Expansion of Biologic Applications in Spinal Fusion, Disc Replacement, and Spinal Deformity Correction Spurs Market Potential
    • Shift Towards Regenerative Medicine, Personalized Spine Care, and Patient-Specific Biologics Expands Market Opportunities
    • Increasing Emphasis on Patient Education, Surgical Guidelines, and Evidence-Based Practice Creates New Opportunities
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Spine Biologics Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Spine Biologics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Spine Biologics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Spine Biologics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Spinal Allografts by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Spinal Allografts by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Spinal Allografts by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Bone Graft Substitutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Bone Graft Substitutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Bone Graft Substitutes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Cell-based Matrix by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Cell-based Matrix by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Cell-based Matrix by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Hospitals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Ambulatory Surgery Centers (ASCs) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Ambulatory Surgery Centers (ASCs) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Ambulatory Surgery Centers (ASCs) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Spine Biologics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 23: USA Recent Past, Current & Future Analysis for Spine Biologics by Product - Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 24: USA Historic Review for Spine Biologics by Product - Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 25: USA 15-Year Perspective for Spine Biologics by Product - Percentage Breakdown of Value Sales for Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix for the Years 2015, 2025 & 2030
    • TABLE 26: USA Recent Past, Current & Future Analysis for Spine Biologics by End-Use - Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 27: USA Historic Review for Spine Biologics by End-Use - Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 28: USA 15-Year Perspective for Spine Biologics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 29: Canada Recent Past, Current & Future Analysis for Spine Biologics by Product - Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 30: Canada Historic Review for Spine Biologics by Product - Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 31: Canada 15-Year Perspective for Spine Biologics by Product - Percentage Breakdown of Value Sales for Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix for the Years 2015, 2025 & 2030
    • TABLE 32: Canada Recent Past, Current & Future Analysis for Spine Biologics by End-Use - Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Canada Historic Review for Spine Biologics by End-Use - Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 34: Canada 15-Year Perspective for Spine Biologics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses for the Years 2015, 2025 & 2030
  • JAPAN
    • Spine Biologics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 35: Japan Recent Past, Current & Future Analysis for Spine Biologics by Product - Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Japan Historic Review for Spine Biologics by Product - Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 37: Japan 15-Year Perspective for Spine Biologics by Product - Percentage Breakdown of Value Sales for Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix for the Years 2015, 2025 & 2030
    • TABLE 38: Japan Recent Past, Current & Future Analysis for Spine Biologics by End-Use - Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Japan Historic Review for Spine Biologics by End-Use - Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 40: Japan 15-Year Perspective for Spine Biologics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses for the Years 2015, 2025 & 2030
  • CHINA
    • Spine Biologics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 41: China Recent Past, Current & Future Analysis for Spine Biologics by Product - Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 42: China Historic Review for Spine Biologics by Product - Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 43: China 15-Year Perspective for Spine Biologics by Product - Percentage Breakdown of Value Sales for Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix for the Years 2015, 2025 & 2030
    • TABLE 44: China Recent Past, Current & Future Analysis for Spine Biologics by End-Use - Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 45: China Historic Review for Spine Biologics by End-Use - Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 46: China 15-Year Perspective for Spine Biologics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses for the Years 2015, 2025 & 2030
  • EUROPE
    • Spine Biologics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 47: Europe Recent Past, Current & Future Analysis for Spine Biologics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 48: Europe Historic Review for Spine Biologics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 49: Europe 15-Year Perspective for Spine Biologics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Spine Biologics by Product - Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for Spine Biologics by Product - Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 52: Europe 15-Year Perspective for Spine Biologics by Product - Percentage Breakdown of Value Sales for Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix for the Years 2015, 2025 & 2030
    • TABLE 53: Europe Recent Past, Current & Future Analysis for Spine Biologics by End-Use - Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for Spine Biologics by End-Use - Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 55: Europe 15-Year Perspective for Spine Biologics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses for the Years 2015, 2025 & 2030
  • FRANCE
    • Spine Biologics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 56: France Recent Past, Current & Future Analysis for Spine Biologics by Product - Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: France Historic Review for Spine Biologics by Product - Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 58: France 15-Year Perspective for Spine Biologics by Product - Percentage Breakdown of Value Sales for Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix for the Years 2015, 2025 & 2030
    • TABLE 59: France Recent Past, Current & Future Analysis for Spine Biologics by End-Use - Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 60: France Historic Review for Spine Biologics by End-Use - Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 61: France 15-Year Perspective for Spine Biologics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses for the Years 2015, 2025 & 2030
  • GERMANY
    • Spine Biologics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 62: Germany Recent Past, Current & Future Analysis for Spine Biologics by Product - Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Germany Historic Review for Spine Biologics by Product - Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 64: Germany 15-Year Perspective for Spine Biologics by Product - Percentage Breakdown of Value Sales for Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix for the Years 2015, 2025 & 2030
    • TABLE 65: Germany Recent Past, Current & Future Analysis for Spine Biologics by End-Use - Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Germany Historic Review for Spine Biologics by End-Use - Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 67: Germany 15-Year Perspective for Spine Biologics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 68: Italy Recent Past, Current & Future Analysis for Spine Biologics by Product - Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Italy Historic Review for Spine Biologics by Product - Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 70: Italy 15-Year Perspective for Spine Biologics by Product - Percentage Breakdown of Value Sales for Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix for the Years 2015, 2025 & 2030
    • TABLE 71: Italy Recent Past, Current & Future Analysis for Spine Biologics by End-Use - Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Italy Historic Review for Spine Biologics by End-Use - Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 73: Italy 15-Year Perspective for Spine Biologics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Spine Biologics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 74: UK Recent Past, Current & Future Analysis for Spine Biologics by Product - Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: UK Historic Review for Spine Biologics by Product - Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 76: UK 15-Year Perspective for Spine Biologics by Product - Percentage Breakdown of Value Sales for Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix for the Years 2015, 2025 & 2030
    • TABLE 77: UK Recent Past, Current & Future Analysis for Spine Biologics by End-Use - Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 78: UK Historic Review for Spine Biologics by End-Use - Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 79: UK 15-Year Perspective for Spine Biologics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 80: Spain Recent Past, Current & Future Analysis for Spine Biologics by Product - Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Spain Historic Review for Spine Biologics by Product - Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 82: Spain 15-Year Perspective for Spine Biologics by Product - Percentage Breakdown of Value Sales for Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix for the Years 2015, 2025 & 2030
    • TABLE 83: Spain Recent Past, Current & Future Analysis for Spine Biologics by End-Use - Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Spain Historic Review for Spine Biologics by End-Use - Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 85: Spain 15-Year Perspective for Spine Biologics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 86: Russia Recent Past, Current & Future Analysis for Spine Biologics by Product - Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Russia Historic Review for Spine Biologics by Product - Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 88: Russia 15-Year Perspective for Spine Biologics by Product - Percentage Breakdown of Value Sales for Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix for the Years 2015, 2025 & 2030
    • TABLE 89: Russia Recent Past, Current & Future Analysis for Spine Biologics by End-Use - Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Russia Historic Review for Spine Biologics by End-Use - Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 91: Russia 15-Year Perspective for Spine Biologics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 92: Rest of Europe Recent Past, Current & Future Analysis for Spine Biologics by Product - Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Rest of Europe Historic Review for Spine Biologics by Product - Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 94: Rest of Europe 15-Year Perspective for Spine Biologics by Product - Percentage Breakdown of Value Sales for Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix for the Years 2015, 2025 & 2030
    • TABLE 95: Rest of Europe Recent Past, Current & Future Analysis for Spine Biologics by End-Use - Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Rest of Europe Historic Review for Spine Biologics by End-Use - Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 97: Rest of Europe 15-Year Perspective for Spine Biologics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Spine Biologics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 98: Asia-Pacific Recent Past, Current & Future Analysis for Spine Biologics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 99: Asia-Pacific Historic Review for Spine Biologics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 100: Asia-Pacific 15-Year Perspective for Spine Biologics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Spine Biologics by Product - Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Asia-Pacific Historic Review for Spine Biologics by Product - Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 103: Asia-Pacific 15-Year Perspective for Spine Biologics by Product - Percentage Breakdown of Value Sales for Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix for the Years 2015, 2025 & 2030
    • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Spine Biologics by End-Use - Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Asia-Pacific Historic Review for Spine Biologics by End-Use - Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 106: Asia-Pacific 15-Year Perspective for Spine Biologics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Spine Biologics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 107: Australia Recent Past, Current & Future Analysis for Spine Biologics by Product - Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Australia Historic Review for Spine Biologics by Product - Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 109: Australia 15-Year Perspective for Spine Biologics by Product - Percentage Breakdown of Value Sales for Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix for the Years 2015, 2025 & 2030
    • TABLE 110: Australia Recent Past, Current & Future Analysis for Spine Biologics by End-Use - Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Australia Historic Review for Spine Biologics by End-Use - Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 112: Australia 15-Year Perspective for Spine Biologics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses for the Years 2015, 2025 & 2030
  • INDIA
    • Spine Biologics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 113: India Recent Past, Current & Future Analysis for Spine Biologics by Product - Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 114: India Historic Review for Spine Biologics by Product - Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 115: India 15-Year Perspective for Spine Biologics by Product - Percentage Breakdown of Value Sales for Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix for the Years 2015, 2025 & 2030
    • TABLE 116: India Recent Past, Current & Future Analysis for Spine Biologics by End-Use - Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 117: India Historic Review for Spine Biologics by End-Use - Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 118: India 15-Year Perspective for Spine Biologics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 119: South Korea Recent Past, Current & Future Analysis for Spine Biologics by Product - Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 120: South Korea Historic Review for Spine Biologics by Product - Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 121: South Korea 15-Year Perspective for Spine Biologics by Product - Percentage Breakdown of Value Sales for Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix for the Years 2015, 2025 & 2030
    • TABLE 122: South Korea Recent Past, Current & Future Analysis for Spine Biologics by End-Use - Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 123: South Korea Historic Review for Spine Biologics by End-Use - Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 124: South Korea 15-Year Perspective for Spine Biologics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 125: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Spine Biologics by Product - Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Rest of Asia-Pacific Historic Review for Spine Biologics by Product - Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 127: Rest of Asia-Pacific 15-Year Perspective for Spine Biologics by Product - Percentage Breakdown of Value Sales for Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix for the Years 2015, 2025 & 2030
    • TABLE 128: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Spine Biologics by End-Use - Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Rest of Asia-Pacific Historic Review for Spine Biologics by End-Use - Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 130: Rest of Asia-Pacific 15-Year Perspective for Spine Biologics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Spine Biologics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 131: Latin America Recent Past, Current & Future Analysis for Spine Biologics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 132: Latin America Historic Review for Spine Biologics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 133: Latin America 15-Year Perspective for Spine Biologics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 134: Latin America Recent Past, Current & Future Analysis for Spine Biologics by Product - Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Latin America Historic Review for Spine Biologics by Product - Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 136: Latin America 15-Year Perspective for Spine Biologics by Product - Percentage Breakdown of Value Sales for Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix for the Years 2015, 2025 & 2030
    • TABLE 137: Latin America Recent Past, Current & Future Analysis for Spine Biologics by End-Use - Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Latin America Historic Review for Spine Biologics by End-Use - Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 139: Latin America 15-Year Perspective for Spine Biologics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 140: Argentina Recent Past, Current & Future Analysis for Spine Biologics by Product - Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Argentina Historic Review for Spine Biologics by Product - Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 142: Argentina 15-Year Perspective for Spine Biologics by Product - Percentage Breakdown of Value Sales for Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix for the Years 2015, 2025 & 2030
    • TABLE 143: Argentina Recent Past, Current & Future Analysis for Spine Biologics by End-Use - Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Argentina Historic Review for Spine Biologics by End-Use - Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 145: Argentina 15-Year Perspective for Spine Biologics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 146: Brazil Recent Past, Current & Future Analysis for Spine Biologics by Product - Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Brazil Historic Review for Spine Biologics by Product - Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 148: Brazil 15-Year Perspective for Spine Biologics by Product - Percentage Breakdown of Value Sales for Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix for the Years 2015, 2025 & 2030
    • TABLE 149: Brazil Recent Past, Current & Future Analysis for Spine Biologics by End-Use - Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Brazil Historic Review for Spine Biologics by End-Use - Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 151: Brazil 15-Year Perspective for Spine Biologics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 152: Mexico Recent Past, Current & Future Analysis for Spine Biologics by Product - Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Mexico Historic Review for Spine Biologics by Product - Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 154: Mexico 15-Year Perspective for Spine Biologics by Product - Percentage Breakdown of Value Sales for Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix for the Years 2015, 2025 & 2030
    • TABLE 155: Mexico Recent Past, Current & Future Analysis for Spine Biologics by End-Use - Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Mexico Historic Review for Spine Biologics by End-Use - Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 157: Mexico 15-Year Perspective for Spine Biologics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 158: Rest of Latin America Recent Past, Current & Future Analysis for Spine Biologics by Product - Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Rest of Latin America Historic Review for Spine Biologics by Product - Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 160: Rest of Latin America 15-Year Perspective for Spine Biologics by Product - Percentage Breakdown of Value Sales for Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix for the Years 2015, 2025 & 2030
    • TABLE 161: Rest of Latin America Recent Past, Current & Future Analysis for Spine Biologics by End-Use - Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Rest of Latin America Historic Review for Spine Biologics by End-Use - Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 163: Rest of Latin America 15-Year Perspective for Spine Biologics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Spine Biologics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 164: Middle East Recent Past, Current & Future Analysis for Spine Biologics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 165: Middle East Historic Review for Spine Biologics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 166: Middle East 15-Year Perspective for Spine Biologics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 167: Middle East Recent Past, Current & Future Analysis for Spine Biologics by Product - Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Middle East Historic Review for Spine Biologics by Product - Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 169: Middle East 15-Year Perspective for Spine Biologics by Product - Percentage Breakdown of Value Sales for Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix for the Years 2015, 2025 & 2030
    • TABLE 170: Middle East Recent Past, Current & Future Analysis for Spine Biologics by End-Use - Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Middle East Historic Review for Spine Biologics by End-Use - Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 172: Middle East 15-Year Perspective for Spine Biologics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 173: Iran Recent Past, Current & Future Analysis for Spine Biologics by Product - Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Iran Historic Review for Spine Biologics by Product - Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 175: Iran 15-Year Perspective for Spine Biologics by Product - Percentage Breakdown of Value Sales for Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix for the Years 2015, 2025 & 2030
    • TABLE 176: Iran Recent Past, Current & Future Analysis for Spine Biologics by End-Use - Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Iran Historic Review for Spine Biologics by End-Use - Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 178: Iran 15-Year Perspective for Spine Biologics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 179: Israel Recent Past, Current & Future Analysis for Spine Biologics by Product - Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Israel Historic Review for Spine Biologics by Product - Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 181: Israel 15-Year Perspective for Spine Biologics by Product - Percentage Breakdown of Value Sales for Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix for the Years 2015, 2025 & 2030
    • TABLE 182: Israel Recent Past, Current & Future Analysis for Spine Biologics by End-Use - Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Israel Historic Review for Spine Biologics by End-Use - Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 184: Israel 15-Year Perspective for Spine Biologics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 185: Saudi Arabia Recent Past, Current & Future Analysis for Spine Biologics by Product - Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Saudi Arabia Historic Review for Spine Biologics by Product - Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 187: Saudi Arabia 15-Year Perspective for Spine Biologics by Product - Percentage Breakdown of Value Sales for Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix for the Years 2015, 2025 & 2030
    • TABLE 188: Saudi Arabia Recent Past, Current & Future Analysis for Spine Biologics by End-Use - Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Saudi Arabia Historic Review for Spine Biologics by End-Use - Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 190: Saudi Arabia 15-Year Perspective for Spine Biologics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 191: UAE Recent Past, Current & Future Analysis for Spine Biologics by Product - Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 192: UAE Historic Review for Spine Biologics by Product - Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 193: UAE 15-Year Perspective for Spine Biologics by Product - Percentage Breakdown of Value Sales for Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix for the Years 2015, 2025 & 2030
    • TABLE 194: UAE Recent Past, Current & Future Analysis for Spine Biologics by End-Use - Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 195: UAE Historic Review for Spine Biologics by End-Use - Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 196: UAE 15-Year Perspective for Spine Biologics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 197: Rest of Middle East Recent Past, Current & Future Analysis for Spine Biologics by Product - Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Rest of Middle East Historic Review for Spine Biologics by Product - Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 199: Rest of Middle East 15-Year Perspective for Spine Biologics by Product - Percentage Breakdown of Value Sales for Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix for the Years 2015, 2025 & 2030
    • TABLE 200: Rest of Middle East Recent Past, Current & Future Analysis for Spine Biologics by End-Use - Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Rest of Middle East Historic Review for Spine Biologics by End-Use - Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 202: Rest of Middle East 15-Year Perspective for Spine Biologics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses for the Years 2015, 2025 & 2030
  • AFRICA
    • Spine Biologics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 203: Africa Recent Past, Current & Future Analysis for Spine Biologics by Product - Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Africa Historic Review for Spine Biologics by Product - Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 205: Africa 15-Year Perspective for Spine Biologics by Product - Percentage Breakdown of Value Sales for Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix for the Years 2015, 2025 & 2030
    • TABLE 206: Africa Recent Past, Current & Future Analysis for Spine Biologics by End-Use - Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Africa Historic Review for Spine Biologics by End-Use - Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 208: Africa 15-Year Perspective for Spine Biologics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses for the Years 2015, 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제